The report said suspension of the trial was having an impact on other AstraZeneca vaccine trials - as well as on clinical trials being conducted by other vaccine makers.
AstraZeneca in June picked Emergent to help produce 300 million doses of its potential COVID-19 vaccine pledged to the United States.
The London-listed company said on Monday it would pay Daiichi an upfront payment of $1 billion for DS-1062, a type of antibody drug conjugate (ADC).
Executives from Johnson & Johnson and AstraZeneca testified that they will price their respective potential vaccines at no profit while the pandemic rages on.
JPOST Digital Library
